Immatics N.V. (NASDAQ:IMTX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Immatics N.V. (NASDAQ:IMTX) have received an average rating of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $19.00.

A number of analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Immatics in a research note on Thursday, January 22nd. Leerink Partners reiterated an “outperform” rating and issued a $17.00 target price on shares of Immatics in a research note on Thursday, December 4th. Mizuho set a $25.00 target price on shares of Immatics in a report on Thursday, February 19th. Wall Street Zen raised shares of Immatics from a “sell” rating to a “hold” rating in a research report on Monday, March 9th. Finally, Jefferies Financial Group started coverage on shares of Immatics in a report on Monday, March 16th. They set a “buy” rating and a $18.00 price target for the company.

Immatics Stock Performance

IMTX opened at $9.51 on Tuesday. The business has a 50 day moving average price of $9.86 and a 200 day moving average price of $9.55. Immatics has a twelve month low of $3.30 and a twelve month high of $12.41. The firm has a market cap of $1.28 billion, a P/E ratio of -5.17 and a beta of 1.34.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.14. Immatics had a negative return on equity of 41.81% and a negative net margin of 411.90%.The company had revenue of $23.00 million for the quarter, compared to the consensus estimate of $12.18 million. As a group, analysts anticipate that Immatics will post -0.72 earnings per share for the current fiscal year.

Institutional Trading of Immatics

Several hedge funds have recently added to or reduced their stakes in IMTX. Jefferies Financial Group Inc. boosted its stake in Immatics by 323.4% during the 4th quarter. Jefferies Financial Group Inc. now owns 5,059,551 shares of the company’s stock valued at $53,125,000 after purchasing an additional 3,864,636 shares during the period. RTW Investments LP increased its position in Immatics by 29.7% in the 4th quarter. RTW Investments LP now owns 11,433,354 shares of the company’s stock worth $120,050,000 after buying an additional 2,617,737 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Immatics by 10.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 21,459,156 shares of the company’s stock worth $225,322,000 after buying an additional 2,075,987 shares during the last quarter. Baker BROS. Advisors LP lifted its holdings in shares of Immatics by 18.9% during the third quarter. Baker BROS. Advisors LP now owns 12,094,094 shares of the company’s stock worth $103,042,000 after buying an additional 1,925,193 shares during the last quarter. Finally, Sofinnova Investments Inc. boosted its position in shares of Immatics by 54.2% in the fourth quarter. Sofinnova Investments Inc. now owns 3,435,542 shares of the company’s stock valued at $36,073,000 after acquiring an additional 1,207,705 shares during the period. Institutional investors own 64.41% of the company’s stock.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.